Abstracts Archive - Page 259 of 2607 - ACR Meeting Abstracts

Abstract Number: 0450 • ACR Convergence 2024
Knowledge, Attitudes, and Intention Towards HPV Vaccination Among Reproductive-Age Women with Rheumatic Diseases
Galilea Rodriguez¹, Ana Rodriguez-Flores², Mara Ponce³, Anahí Carrazco Chapa⁴, Karen Aglae Chavez-Olivo¹, Aldo Patricio Romero-Avila¹, Jesus Cardenas-de la Garza³, CASSANDRA SKINNER TAYLOR⁵, Lorena Perez-Barbosa⁶ and Dionicio Galarza-Delgado⁷, ¹Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico, ²Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ⁵HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁶Hospital Universitario, UANL, Monterrey, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Women with autoimmune rheumatic disease (ARDs) have a higher risk for cervical cancer due to the persistence of the HPV infection. HPV vaccination is…
Abstract Number: 0398 • ACR Convergence 2024
Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data
Mary Eckert¹, Eveline Wu², Melissa Oliver³, Joshua Scheck⁴, Sivia Lapidus⁵, Ummusen Kaya Akca⁶, Shima Yasin⁷, Aleksander Lenert⁸, Sara Stern⁹, Antonella insalaco¹⁰, Manuela Pardeo¹⁰, Gabriele Simonini¹¹, Edoardo Marrani¹², Xing Wang¹³, Bin Huang¹⁴, Leonard Kovalick¹⁵, Natalie Rosenwasser¹⁶, Erin Balay-Dustrude¹⁷, Gabriel Casselman¹⁶, Liau Adriel¹⁸, Ava Klein¹⁸, Yurong Shao⁴, Claire Yang⁴, Molly Briggs⁴, Emily Deng⁴, Iris Hamilton⁴, Ethan Mueller¹⁶, Elise Machrone⁴, Paige Trunnel⁴, Doaa Mosa¹⁹, Lori Tucker²⁰, Hermann Girschick²¹, Ronald Laxer²², Georgina Tiller²³, Jonathan Akikusa²⁴, Christian Hedrich²⁵, Karen Onel²⁶, Fatma Dedeoglu²⁷, Marinka Twilt²⁸, Seza Ozen²⁹, Polly Ferguson³⁰, Laura Schanberg³¹, Bryce Reeve³² and Yongdong (Dan) Zhao³³, ¹Seattle Children's, Mercer Island, WA, ²University of North Carolina School of Medicine, Chapel Hill, NC, ³Indiana University, Indianapolis, IN, ⁴Seattle Children's Hospital, Seattle, ⁵Hackensack University Medical Center, Montclair, NJ, ⁶Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁷University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, ⁸University of Iowa, Iowa City, IA, ⁹University of Utah, Salt Lake City, UT, ¹⁰IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹¹Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹²University of Florence, Firenze, Florence, Italy, ¹³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ¹⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ¹⁵UNC Health Care, Durham, NC, ¹⁶Seattle Children's Hospital, Seattle, WA, ¹⁷University of Washington, Seattle, WA, ¹⁸Seattle Children’s Research Institute, University of Washington, Seattle, ¹⁹Mansoura University Hospital, Mansoura City, Egypt, ²⁰BC Children's Hospital, Vancouver, BC, Canada, ²¹Vivantes Clinic Friedrichshain, Wuerzburg, Germany, ²²SickKids, Toronto, ON, Canada, ²³University of British Columbia - Vancouver, Vancouver, BC, Canada, ²⁴Royal Children's Hospital, Parkville, Victoria, Australia, ²⁵University of Liverpool, Liverpool, United Kingdom, ²⁶HSS, New York, NY, ²⁷Boston Children's Hospital, Boston, MA, ²⁸Alberta Children's Hospital, Calgary, AB, Canada, ²⁹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ³⁰University of Iowa Carver College of Medicine, Iowa City, IA, ³¹Duke University Medical Center, DURHAM, NC, ³²Duke University School of Medicine, Durham, ³³University of Washington, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
Abstract Number: 0482 • ACR Convergence 2024
Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis
Vanshika Sabharwal¹ and Ashit Syngle², ¹MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India, ²Healing Touch City Clinic, Chandigarh, Chandigarh, India
Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…
Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Priyanka Yalamanchili¹, Lydia Lee², Greta Bushnell³, Melissa Mannion⁴, Chintan Dave⁵ and Daniel B. Horton⁶, ¹Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research, Morris Plains, NJ, ²Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, NJ, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ, ⁶Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…
Abstract Number: 0472 • ACR Convergence 2024
Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Bas Dijkshoorn¹, Sreen Mohamed², Romy Hansildaar², Henk Everaars³, Geoffrey Mooij³, Luuk Hopman³, Paul Knaapen³, Lourens Robbers³ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology center location Reade, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…
Abstract Number: 0418 • ACR Convergence 2024
Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
Megan Clowse¹, Puneet Bajaj², Bonnie Bermas², Julie Chiesa³, Kathryn Dao⁴, Pamela Freeman⁵, Bansari Gujar⁶, Brittany Hill⁷, Kelley Jones⁸, Richard Jones⁹, Ann Marslett¹⁰, Brooke Mills¹¹, James Roberts², Amanda Snyderman⁸ and Leah Zulig¹², ¹Duke University, Chapel Hill, NC, ²UT Southwestern Medical Center, Dallas, TX, ³InfoDirectors, Durham, NC, ⁴Rheum101, Rockville, MD, ⁵Rheumatology Associates of Central Florida, Orlando, FL, ⁶Rheumatology Associates of Baltimore, Towson, MD, ⁷Clinic for Rheumatic Disease, Tuscaloosa, AL, ⁸Duke University School of Medicine, Durham, ⁹Clinic for Rheumatic Diseases, Northport, AL, ¹⁰Rheumatology Associates of Baltimore, Baltimore, MD, ¹¹UT Southwestern Medical Center, Fort Worth, TX, ¹²Duke University School of Medicine, Durham, NC
Background/Purpose: Prior studies of RISE Registry found 9-11% of women of reproductive age with contraception documentation. We sought to identify and assess methods to increase contraception documentation…
Abstract Number: 0466 • ACR Convergence 2024
Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample
Karun Shrestha¹, Prakriti Subedi², Manoj Ghimire³, Sajana Poudel⁴, Keerthi Parvathaneni⁵, Mahmoud Hashim⁶, Kalpana Ghimire⁵, Oshna Pandey⁵, Mohammed Hasan⁷, Clement Tagoe⁸ and Liliya Gandrabur⁹, ¹St. Barnabas Hospital Internal Medicine Residency, Bronx, NY, ²St. Barnabas Hospital, Bronx, NY, ³St Barnabas Hospital, BRONX, NY, ⁴Cook County Health, CHICAGO, NY, ⁵Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA, Bronx, NY, ⁶SBH Health System, New Rochelle, NY, ⁷Parkview Medical Center, Pueblo, CO, ⁸Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁹SBH Health System, Forest Hills, NY
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, effective pain management remains challenging, with many patients also experiencing insomnia, anxiety, and depression. As cannabis legalization…
Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose Felix Restrepo Suarez¹, Carlos Lorenzo¹, Inmaculada Del rincon² and Agustin Escalante¹, ¹UT Health San Antonio, San Antonio, TX, ²UT Health San Antonio, San Antonio
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
Abstract Number: 0483 • ACR Convergence 2024
Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD
Misti Paudel¹, Shravani Chitineni¹, Ruogu Li², Chinmayi Naik³, Nancy Shadick³, Michael Weinblatt⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Prior studies have evaluated the risk factors for difficult-to-treat RA (D2T-RA) but have not applied EULAR’s full criteria for D2T-RA in a longitudinal data…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 0494 • ACR Convergence 2024
Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Ventura Mejia², guillermo velarde² and Graciela Alarcon³, ¹Hncase, Arequipa, Peru, ²UNIVERSIDAD NACIONAL DE SAN AGUSTIN, arequipa, Peru, ³The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) causes systemic inflammation that leads to specific changes in the patients’ blood cells; this offers the opportunity to measure inflammatory activity…
Abstract Number: 0509 • ACR Convergence 2024
Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
Lydia Lee¹, Jeffrey Sparks², Priyanka Yalamanchili¹, Daniel B. Horton³, Zeba Khan⁴, Joseph Barone⁴ and Chintan Dave⁵, ¹Rutgers University, New Brunswick, NJ, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Rutgers University, New Brunswick, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ
Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…
Abstract Number: 0389 • ACR Convergence 2024
Histopathological Features of Liver Tissue Biopsies in SJIA Patients with and Without Clinical Macrophage Activation Syndrome
Esraa Eloseily¹, Lara Berklite², Jennifer Picarsic¹, grant schulert¹, Rachel Sheridan¹ and Alexei Grom¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnti, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) can present with or without Macrophage Activation Syndrome (MAS), a severe, potentially life-threatening complication. Liver tissue injury is commonly…
Abstract Number: 0419 • ACR Convergence 2024
Placental Weights of Offspring Born to Women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Eugenia Chock¹, Zeyan Liew², Lars Henning Pedersen³ and Mette Oestergaard Thunbo³, ¹Yale School of Medicine, New Haven, CT, ²Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven, CT, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Offspring of patients with chronic inflammatory arthritis have almost double the risk of being born small for gestational age. Placental insufficiency is one of…
Abstract Number: 0402 • ACR Convergence 2024
Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts
Mariana Correia Marques¹, Erin Balay-Dustrude², Claudia Bracaglia³, Marinka Twilt⁴, Karen Onel⁵, Simone Appenzeller⁶, Fatma Dedeoglu⁷, Esraa Eloseily⁸, Penelope Martinez Jimenez⁹, Rebecca Trachtman¹⁰, Francesca Minoia¹¹ and Susan Shenoi¹², and on behalf of the MAS/sJIA WP of PReS and CARRA sJIA Workgroup, ¹National Institutes of Health, Bethesda, MD, ²University of Washington, Seattle, WA, ³IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴Alberta Children's Hospital, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada, Calgary, AB, Canada, ⁵HSS, New York, NY, ⁶Department of Orthopedics, Rheumatology and Traumatology. University of Campinas, Campinas, Brazil, ⁷Boston Children's Hospital, Boston, MA, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Icahn School of Medicine at Mount Sinai- Elmhurst Hospital Center, Rego Park, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ¹²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: Multinational research is essential to globally improve the management of systemic juvenile idiopathic arthritis (sJIA), improve recognition of rare complications like lung disease, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].